Gastric cancer
Conditions
Interventions
The treatment consisted in the administration of 85 mg/m2 oxaliplatin and 200 mg/m2 LV by a 2-h intravenous infusion, followed by the administration of 400 mg/m2 bolus 5-FU and 2400 mg/m2 5-FU by a 46
Sponsors
Kyoto Katsura Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically proven gastric adenocarcinoma 2) Age above 20 years old 3) ECOG performance status of 0 or 1 4) Adequate organ function 1. WBC:>=3,000/mm3,<12,000/mm3 2. Neutrophil:>=1,500/mm3 3. Platelet:>=100,000/mm3 4. Hemoglobin:>=9.0g/dL 5. AST(GOT)/ALT(GPT):<=100 IU/L 6. Total bilirubin:<=2.0mg/dL 5) Written informed consent from patient 6)Patients undergoing exposure to immune checkpoint inhibitors in advanced gastric cancer
Exclusion criteria
Exclusion criteria: 1) Severe complications 2) With active infection 3) Past history of severe hypersensitivity to drugs 4) Pregnant women, or women with the possibility of the pregnancy, Men who want let to pregnancy 5) Patients judged inappropriate for the study by the physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events Disease control rate Progression-free survival Overall survival | — |
Countries
Japan
Contacts
Public ContactSayuri Konishi
Kyoto Katsura Hospital Department of Surgery, Gastro-Intestinal Center
Outcome results
None listed